Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 3:52 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1681–1704 of 11,419 matching trials from the live ClinicalTrials.gov search.

Filters: Seattle, Washington Clear all

Conditions: Pancreatic Cancer
Interventions: SM-88 used with MPS (methoxsalen, phenytoin, sirolimus), Capecitabine, Gemcitabine, and 5-FU; Drug
Lead sponsor: Tyme, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 20
States / cities: Birmingham, Alabama • Duarte, California • Santa Monica, California + 13 more

Conditions: Advanced Solid Tumors, HNSCC, SCLC, NSCLC, TNBC - Triple-Negative Breast Cancer, CRC
Interventions: TUB-030; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 13
States / cities: New Haven, Connecticut • Miami, Florida • Boston, Massachusetts + 9 more

Conditions: Hepatitis C, Chronic
Interventions: Ribavirin, Peginterferon alfa-2a; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 569 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 58
States / cities: Scottsdale, Arizona • Tucson, Arizona • Anaheim, California + 46 more

Conditions: Stress Urinary Incontinence
Interventions: GTx 024, Placebo; Drug
Lead sponsor: GTx; Industry
Eligibility: 18 Years to 80 Years · Female only
Enrollment: 491 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 62
States / cities: Homewood, Alabama • Mobile, Alabama • Anchorage, Alaska + 57 more

Conditions: Colorectal Neoplasms
Interventions: Amivantamab, Cetuximab, 5-fluorouracil, Leucovorin calcium/Levoleucovorin, Oxaliplatin, Irinotecan Hydrochloride; Biological · Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2032
U.S. locations: 81
States / cities: Gilbert, Arizona • Jonesboro, Arkansas • Springdale, Arkansas + 67 more

Conditions: Sarcoma
Interventions: topotecan hydrochloride; Drug
Lead sponsor: Gynecologic Oncology Group; Network
Eligibility: Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1998
U.S. locations: 45
States / cities: Birmingham, Alabama • Los Angeles, California • Los Gatos, California + 39 more

Conditions: Disease, Hodgkin
Interventions: brentuximab vedotin, placebo; Drug
Lead sponsor: Seagen Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 329 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2020
U.S. locations: 32
States / cities: Duarte, California • San Francisco, California • Stanford, California + 26 more

Conditions: Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Acute Myelomonocytic Leukemia (M4), Adult Erythroleukemia (M6a), Adult Pure Erythroid Leukemia (M6b), Secondary Acute Myeloid Leukemia, Untreated Adult Acute Myeloid Leukemia
Interventions: alvocidib, mitoxantrone hydrochloride, cytarabine, pharmacological study, laboratory biomarker analysis; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 2
States / cities: Baltimore, Maryland • Seattle, Washington

Conditions: Back Pain
Interventions: Not listed
Lead sponsor: Kaiser Permanente; Other
Eligibility: 18 Years and older
Enrollment: 1,760 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Vascular Surgical Bleeding
Interventions: Fibrin Sealant Grifols, Manual Compression; Biological · Procedure
Lead sponsor: Instituto Grifols, S.A.; Industry
Eligibility: Not listed
Enrollment: 225 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 27
States / cities: Florence, Alabama • Palo Alto, California • San Diego, California + 23 more

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Pembrolizumab, Cisplatin, Carboplatin, Pemetrexed, Gemcitabine, Paclitaxel, Intismeran autogene, Placebo; Biological · Drug · Other
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 680 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2038
U.S. locations: 54
States / cities: Gilbert, Arizona • Tucson, Arizona • Fullerton, California + 42 more

Conditions: Kidney Transplantation
Interventions: Alefacept, tacrolimus, basiliximab, mycophenolate mofetil, Corticosteroids; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 18 Years and older
Enrollment: 323 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 38
States / cities: Loma Linda, California • Los Angeles, California • Sacramento, California + 28 more

Conditions: Hot Flashes
Interventions: Brisdelle (paroxetine mesylate), Placebo capsules; Drug
Lead sponsor: Noven Therapeutics; Industry
Eligibility: 40 Years and older · Female only
Enrollment: 570 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 32
States / cities: Montgomery, Alabama • Chandler, Arizona • San Diego, California + 28 more

Conditions: Coronary Artery Disease
Interventions: Prevail DCB, Agent DCB; Device
Lead sponsor: Medtronic Vascular; Industry
Eligibility: 18 Years and older
Enrollment: 1,205 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 55
States / cities: Birmingham, Alabama • Huntsville, Alabama • Tucson, Arizona + 48 more

Conditions: Human Papillomavirus (HPV) 16+ Relapsed/Refractory Cancer
Interventions: KITE-439, Cyclophosphamide, Fludarabine, Interleukin-2; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 9
States / cities: Gilbert, Arizona • Duarte, California • Los Angeles, California + 6 more

Conditions: Pancreatic Leak, Pancreatic Fistula, Pancreaticoduodenal; Fistula, Pancreatectomy; Hyperglycemia
Interventions: Lanreotide Prefilled Syringe; Drug
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 114 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Graft Vs Host Disease, Inflammatory Bowel Diseases, Functional Gastrointestinal Disorders
Interventions: Not listed
Lead sponsor: Boston Children's Hospital; Other
Eligibility: Not listed
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2032
U.S. locations: 4
States / cities: Boston, Massachusetts • Seattle, Washington

Conditions: Infertility
Interventions: FSH-IBSA, GONAL-F; Drug
Lead sponsor: IBSA Institut Biochimique SA; Industry
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 4
States / cities: Palo Alto, California • San Diego, California • San Francisco, California + 1 more

Conditions: HIV Infections
Interventions: rgp120/HIV-1MN; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Ends 1999
U.S. locations: 3
States / cities: Birmingham, Alabama • Rochester, New York • Seattle, Washington

Conditions: Non Small Cell Lung Cancer (NSCLC)
Interventions: Dacomitinib, Doxycycline, Probiotic, Alclometasone cream; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 236 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 79
States / cities: Duarte, California • Fullerton, California • Irvine, California + 49 more

Conditions: Cervical Spinal Cord Injury
Interventions: VX-210, Placebo; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 14 Years to 75 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 33
States / cities: Birmingham, Alabama • Tucson, Arizona • Fresno, California + 30 more

Conditions: HIV Infections
Interventions: gp160 Vaccine (Immuno-AG); Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Ends 1995
U.S. locations: 2
States / cities: St Louis, Missouri • Seattle, Washington

Conditions: Infertility
Interventions: Follitropin delta, Placebo; Drug · Other
Lead sponsor: Ferring Pharmaceuticals; Industry
Eligibility: 18 Years to 34 Years · Female only
Enrollment: 579 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 23
States / cities: Tempe, Arizona • Encino, California • Farmington, Connecticut + 20 more

Conditions: Anaplastic Thyroid Cancer, Recurrent Thyroid Cancer
Interventions: efatutazone, paclitaxel; Drug
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2023
U.S. locations: 253
States / cities: Anchorage, Alaska • Phoenix, Arizona • Scottsdale, Arizona + 168 more

Search by objective public record fields.

A Randomized Phase 2/3 Multi-Center Study of SM-88 in Participants With Metastatic Pancreatic Cancer

First in Human Study of TUB-030 in Patients With Advanced Solid Tumors

Latino Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) and COPEGUS (Ribavirin) in Treatment-Naive Patients With Chronic Hepatitis C-Genotype 1.

Study to Assess Enobosarm (GTx-024) in Postmenopausal Women With Stress Urinary Incontinence

A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer

Topotecan in Treating Patients With Recurrent or Refractory Cancer of the Uterus

A Phase 3 Study of Brentuximab Vedotin (SGN-35) in Patients at High Risk of Residual Hodgkin Lymphoma Following Stem Cell Transplant (The AETHERA Trial)

Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

Matching Appropriate Treatments to Consumers' Healthcare Needs, MATCH

Safety and Efficacy Study of Fibrin Sealant Grifols as an Adjunct to Hemostasis During Peripheral Vascular Surgery

A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

A Study to Assess the Safety and Efficacy of Alefacept in Kidney Transplant Recipients

24-Week Efficacy & Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms

Prevail Global Study

Study to Evaluate the Safety and Efficacy of KITE-439 in HLA-A*02:01+ Adults With Relapsed/Refractory HPV16+ Cancers

A Phase II Trial of Lanreotide for the Prevention of Postoperative Pancreatic Fistula

Precision Diagnostics in Inflammatory Bowel Disease, Cellular Therapy and Transplantation (The PREDICT Trial)

Clinical Efficacy and Tolerability of Two FSH Preparations (Human FSH Versus rFSH - Follitropin Alpha) in Women Undergoing IVF

A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled HIV-1 Vaccine Trial to Evaluate the Safety and Immunogenicity of Low Dose MN rsgp120/HIV-1 (Genentech) in Combination With QS21 Adjuvant or Alum in Healthy Adults

Study Of Dacomitinib (PF-00299804) In Advanced NSCLC Patients (Post Chemo Or Select First Line) To Evaluate Prophylactic Intervention On Derm And GI AEs And PRO

Study to Assess the Efficacy and Safety of VX-210 in Subjects With Acute Traumatic Cervical Spinal Cord Injury

A Phase I, Multicenter, Clinical Trial to Evaluate the Safety and Immunogenicity of Vaccinia-Derived MN HIV-1 Recombinant Envelope Glycoprotein (rgp160) of Human Immunodeficiency Virus at Two Different Vaccination Schedules

Recombinant FSH Investigation in the Treatment of Infertility With Assisted Reproductive Technology (ART) (RITA-1)

Inolitazone Dihydrochloride and Paclitaxel in Treating Patients With Advanced Anaplastic Thyroid Cancer